Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided key program updates, including new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta (CHD). Participants receiving the combination therapy of tobevibart, an investigational neutralizing monoclonal antibody (mAb), and elebsiran, an investigational small interfering RNA (siRNA), showed increased and sustained viral suppression of HDV RNA versus treatment with the antibody alone in p.

Business Wire • Jan 12, 2026

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 at 3:45 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotechnology.

Business Wire • Jan 5, 2026

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty pharmaceutical company, an exclusive license for the commercial rights to the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD) in Europe, Australia and New Zealand. Per the terms of the agreement, Vir Biotechnology will receive an initial reimbursement payment.

Business Wire • Dec 16, 2025

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

Business Wire • Nov 19, 2025

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company's Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants receiving a monthly dose of the combination of tobevibart and elebsiran achieved robust and sustained rates of hepatitis delta virus (HDV) RNA target not detected (TND), including those participants with cirrhosis and high baseline HDV RNA. The combination also showed alanin.

Business Wire • Nov 9, 2025

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

Business Wire • Nov 7, 2025

Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript

Vir Biotechnology, Inc. ( VIR ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jason O'Byrne - Executive VP & CFO Marianne De Backer - CEO & Director Mark Eisner - Executive VP & Chief Medical Officer Conference Call Participants Kun Wang - Barclays Bank PLC, Research Division Rohit Bhasin - Morgan Stanley, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Mario Joshua Chazaro Cortes - Evercore ISI Institutional Equities, Research Division Ellen Horste - TD Cowen, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Joseph Stringer - Needham & Company, LLC, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, and welcome to Vir Biotechnology's Third Quarter 2025 Financial Results and Corporate Update Call.

Seeking Alpha • Nov 6, 2025

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2025. "Our third quarter demonstrated exceptional execution across our clinical portfolio," said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. "We completed ECLIPSE 1 enrollment approximately two months ahead of schedule and continue to see strong momentum across ECLIPSE 2 and 3, positioning us well fo.

Business Wire • Nov 5, 2025

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $1.56 per share a year ago.

Zacks Investment Research • Nov 5, 2025